Literature DB >> 19475428

Use of recombinant human serum albumin in pediatric patients with nephrotic syndrome.

Kazushi Tsuruga, Eishin Oki, Tomomi Yashiro, Etsuro Ito, Hiroshi Tanaka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19475428     DOI: 10.1007/s00467-009-1221-y

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


× No keyword cloud information.
  6 in total

Review 1.  Production of human albumin solution: a continually developing colloid.

Authors:  P Matejtschuk; C H Dash; E W Gascoigne
Journal:  Br J Anaesth       Date:  2000-12       Impact factor: 9.166

2.  Physicochemical and immunochemical properties of recombinant human serum albumin from Pichia pastoris.

Authors:  W Ohtani; Y Nawa; K Takeshima; H Kamuro; K Kobayashi; T Ohmura
Journal:  Anal Biochem       Date:  1998-02-01       Impact factor: 3.365

3.  Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome.

Authors:  Rajmohan Dharmaraj; Pankaj Hari; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2009-01-14       Impact factor: 3.714

4.  Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis: a multicenter clinical study.

Authors:  Akinori Kasahara; Keiji Kita; Eiichi Tomita; Jouji Toyota; Yasuharu Imai; Hiromitsu Kumada
Journal:  J Gastroenterol       Date:  2008-07-04       Impact factor: 7.527

Review 5.  Summary of recombinant human serum albumin development.

Authors:  Kaoru Kobayashi
Journal:  Biologicals       Date:  2006-02-07       Impact factor: 1.856

6.  A comparative pharmacokinetic study of recombinant human serum albumin with plasma-derived human serum albumin in patients with liver cirrhosis.

Authors:  Kunihiko Ohnishi; Atsuhiro Kawaguchi; Shunji Nakajima; Hiroyuki Mori; Takahiro Ueshima
Journal:  J Clin Pharmacol       Date:  2008-02       Impact factor: 3.126

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.